(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Ageless Tastefulness: An Outline of Valuable Gemstones and Adornments - 2ISS astronaut evacuation shouldn't interfere with upcoming Artemis 2 moon mission, NASA chief says
- 3Native Americans had dice and games of probability long before other cultures, study finds
- 4Shrewd Home Gadgets to Save Energy
- 5Ice Spice's 'Big Guy' SpongeBob song is stuck in everyone's heads again — and TikTok is fueling it
- The Most Compelling Innovation Developments Somewhat recently
- The many ways that baking is winter therapy. With a delicious ending
- Poll: Only 25% of Americans think Trump has 'followed through' on his promise to release the Epstein files
- Very good quality Greens All over The Planet
- January full moon wows skywatchers with a striking 'Wolf Supermoon' (photos)
- Governments take targeted action as fuel prices hit retail
- 10 Fundamental Tips and Deceives to Lift Your Cell phone's Exhibition
- NASA shares first photos of Earth taken by Artemis II
- The 10 Most Noteworthy Games in History
